



Organogenesis Unveils Plans for New Biomanufacturing Facility in Smithfield, Rhode Island

Organogenesis Smithfield will add manufacturing, R&D and logistics capabilities supporting existing and planned products designed to advance innovation and regenerative solutions

SMITHFIELD, R.I. – Organogenesis Holdings Inc. (ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced plans to begin manufacturing design and infrastructure construction at the company’s new biomanufacturing facility in Smithfield, Rhode Island.

The 122,000-square-foot facility located at 100 Technology Way, will comprise manufacturing, laboratory, warehousing, and distribution capabilities to support the current advanced wound care portfolio and future product growth initiatives.

Initial investments at the site will be focused on expanding the existing infrastructure that will enable plans to resume commercial production of Dermagraft, ® a human fibroblast-derived dermal substitute FDA-approved to treat diabetic foot ulcers (DFUs). Additional planned investments in the facility will support Organogenesis’ leading regenerative medicine portfolio, including the Apligraf and PuraPly brands.

Gary S. Gillheeney Sr., President, CEO and Chair of the Board of Organogenesis, stated the facility at 100 Technology Way “represents our commitment to growing the company’s footprint in New England, the nation’s preeminent life sciences hub.”

“Our vision for this facility is to be a catalyst for the Rhode Island life sciences industry and to foster continued regional cooperation in biotechnology,” added Gillheeney.

“We are proud to welcome Organogenesis to Rhode Island and our growing life science community,” said Mark A. Turco, MD, President & CEO of the R.I. Life Science Hub.

“The new biomedical manufacturing facility in Smithfield will produce cutting-edge products to aid in the care of patients in need, create high-quality jobs, and serve as another great spark for continued investment in our growing innovation economy added Turco.”

Gillheeney concluded “This state-of-the-art facility will allow us to remain on the leading edge of advancements in regenerative medicine with added capacity to expand upon our multiple technology platforms and bring new innovations to patients, enabling our growth plans for many years to come.”

Organogenesis is planning a multi-year investment of approximately \$100 million in additional improvements in the Smithfield facility. 100 Tech Way will be a cornerstone of Rhode Island’s growing life sciences and biomanufacturing sectors. The site is expected to support more than 200 full-time roles, with potential further expansion creating additional jobs.

About Organogenesis Holdings Inc.

Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com.

Tuesday, May 20, 2025